SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria.
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The objective of this trial was to determine the effectiveness of 1.0% C31G (SAVVY) in preventing male-to-female vaginal transmission of HIV infection among women at high risk. METHODOLOGY/PRINCIPAL FINDINGS: This was a Phase 3, double-blind, randomized, placebo-controlled trial. Participants made up to 12 monthly follow-up visits for HIV testing, adverse event reporting, and study product supply. The study was conducted between September 2004 and December 2006 in Lagos and Ibadan, Nigeria, where we enrolled 2153 HIV-negative women at high risk of HIV infection. Participants were randomized 1 ratio 1 to SAVVY or placebo. The effectiveness endpoint was incidence of HIV infection as indicated by detection of HIV antibodies in oral mucosal transudate (rapid test) or blood (ELISA), and confirmed by Western blot or PCR testing. We observed 33 seroconversions (21 in the SAVVY group, 12 in the placebo group). The Kaplan-Meier estimates of the cumulative probability of HIV infection at 12 months were 0.028 in the SAVVY group and 0.015 in the placebo group (2-sided p-value for the log-rank test of treatment effect 0.121). The point estimate of the hazard ratio was 1.7 for SAVVY versus placebo (95% confidence interval 0.9, 3.5). Because of lower-than-expected HIV incidence, we did not observe the required number of HIV infections (66) for adequate power to detect an effect of SAVVY. Follow-up frequencies of adverse events, reproductive tract adverse events, abnormal pelvic examination findings, chlamydial infections and vaginal infections were similar in the study arms. No serious adverse event was attributable to SAVVY use. CONCLUSIONS/SIGNIFICANCE: SAVVY did not reduce the incidence of HIV infection. Although the hazard ratio was higher in the SAVVY than the placebo group, we cannot conclude that there was a harmful treatment effect of SAVVY.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonspecific topical microbicides are ineffective for preventing HIV infection (40–45).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181 · cited 1×
“We calculated Kaplan-Meier estimates [17] of HIV infection probabilities by treatment group, pooled across sites.”
MethodNonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-2 · Cited by 2,755 · cited 1×
“[1] We conducted this study under an IND to the U.”
MethodDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 1×
“[14–15] The analysis plan included a blinded assessment of whether additional participants would be needed to observe the required 66 events.”
MethodDiscrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Van Damme, L., Ramjee, G., Alary, M., Vuylsteke, B., Chandeying, V., Rees, H., Sirivongrangson, P., Tshibaka, L. M., Ettiègne-Traoré, V., Uaheowitchai, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11079-8 · Cited by 797 · cited 1×
“[6,7] C31G (SAVVYH) has a potent effect on enveloped HIV in vitro through a mechanism by which it disrupts the outer membrane.”
Kreiss, J. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490040053025 · Cited by 402 · cited 1×
“[6,7] C31G (SAVVYH) has a potent effect on enveloped HIV in vitro through a mechanism by which it disrupts the outer membrane.”
BackgroundRoddy, R. E., Zekeng, L., Ryan, K. A., Tamoufé, U., Weir, S. S., & Wong, E. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390803 · Cited by 366
Cited by
Items 201–280 of 280
Ramjee, G., & Whitaker, C. (2011) · InTech eBooks · doi:10.5772/19196 · Cited by 5
“N9 was succeeded by another surfactant gel product called SAVVY, which although safe, was not conclusively found to be of utility in preventing HIV infection (Peterson et al., 2007; Feldblum et al., 2008).”
BackgroundEarly Events in Vaginal Hiv Transmission: Implications in Microbicide Development
Saïdi, H., Jenabian, M.-A., & Bélec, L. (2009) · Future Virology · doi:10.2217/fvl.09.10 · Cited by 5
First Real Success For Anti-Hiv Gel: A New Start For HIV Microbicides?
Ariën, K. K., & Vanham, G. (2010) · Future Microbiology · doi:10.2217/fmb.10.129 · Cited by 5
Eid, S. G., Mangan, N. E., Hertzog, P. J., & Mak, J. (2015) · Clinical & Translational Immunology · doi:10.1038/cti.2015.23 · Cited by 7
Espermicidas: Una alternativa de anticoncepción para considerar
Uribe-Clavijo, M., Medina, L. F. O., Álvarez, Á. M., Cortés-Mancera, F., Cadavid-Jaramillo, Á. P., & Cardona-Maya, W. D. (2012) · TecnoLógicas · doi:10.22430/22565337.17 · Cited by 4
Microbicides for Topical HIV Immunoprophylaxis: Current Status and Future Prospects
Zhernov, Y. V., Petrova, V. O., Simanduyev, M. Y., Shcherbakov, D. V., Полибин, Р. В., Mitrokhin, O. V., Basov, A. A., Zabroda, N. N., Высочанская, С. О., Al-khaleefa, E., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17060668 · Cited by 4
“The Nigerian trial with SAVVY vaginal gel represented no significant differences among participants receiving SAVVY compared with those receiving a placebo [26].”
MethodBreitkopf, C. R., Loza, M. L., Vincent, K. L., Moench, T. R., Stanberry, L. R., & Rosenthal, S. L. (2011) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e318231575f · Cited by 4
A simpler tool for estimation of HIV incidence from cross-sectional, age-specific prevalence data
Rajan, S. S., & Sokal, D. C. (2010) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2009.091959 · Cited by 4
“The estimation method (the method) discussed in this paper provides a relatively simple and rapid method of estimating age-specific incidence under circumstances where little is known about the historic disease prevalence. In order to validate the spreadsheet method, we used data from two clinical trials of vaginal mi…”
MethodStatistical and methodological issues in microbicide trial design
Crook, A. M., & Nunn, A. (2012) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2011.12.008 · Cited by 5
Romero, J. A. F., Gil, P. I., Re, V. E., Robbiani, M., & Paglini, M. G. (2014) · Revista Argentina de Microbiología · doi:10.1016/s0325-7541(14)70080-x · Cited by 10
Development of a prospective cohort of HIV Exposed Sero-Negative (HESN) individuals in Jos Nigeria
Osawe, S., Okpokoro, E., Datiri, R., Choji, G., Okolo, F., Datong, P., & Abimiku, A. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1649-1 · Cited by 3
“Despite this, no HIV vaccine trial has been conducted in Nigeria although it participated in a microbiocide trial that was stopped due to a recorded low HIV incidence [5].”
BackgroundHbAHP‐25 attenuates HIV‐1 gp120 mediated inflammation and barrier dysfunction
Bashir, T., & Reddy, K. (2017) · HIV Medicine · doi:10.1111/hiv.12569 · Cited by 3
Lorenzetti, L., Dinh, N., Whitcomb, C., Martínez, A., Chatani, M., Lievense, B., Nhamo, D., Slack, C. M., Eley, N. T., & MacQueen, K. M. (2024) · AIDS and Behavior · doi:10.1007/s10461-024-04459-z · Cited by 3
“A lack of access to contraceptives and high rates of pregnancy likely undermined the SAVVY and Cellulose Sulfate trials conducted in Western Africa, which were stopped early due to lack of effectiveness [79, 94].”
BackgroundResultAbaasa, A. M., Todd, J., Mayanja, Y., Price, M. A., Fast, P., Kaleebu, P., & Nash, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-51879-2 · Cited by 3
Abaasa, A. M., Todd, J., Nash, S., Mayanja, Y., Kaleebu, P., Fast, P., & Price, M. A. (2020) · BMC Medical Research Methodology · doi:10.1186/s12874-020-00920-4 · Cited by 3
Gisselquist, D. (2013) · Springer eBooks · doi:10.1007/978-94-007-6407-1_16 · Cited by 3
Targeted Combination HIV Prevention Packages to Halt the Global HIV Epidemic
Ramjee, G. (2012) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.s4-002 · Cited by 3
“These include surfactants [99-101] acid buffers [102], and polyanions [103106].”
Should microbicides be controlled by women or by physicians?
Piret, J., & Bergeron, M. G. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2010.02.2256 · Cited by 3
Saïdi, H. (2008) · Reviews in Medical Virology · doi:10.1002/rmv.601 · Cited by 3
“Recent disappointing failure in microbicide clinical trial [5,6] revealed that there are major gaps in knowledge and in the availability of specialised skills and facilities that prevent the field from moving forward at a pace commensurate with the urgency of the need for microbicides.”
BackgroundPADIAN, N. S., Buvé, A., Balkus, J. E., Serwadda, D., & Cates, W. (2008) · Cited by 3
Abaasa, A. M., Gafos, M., Anywaine, Z., Nunn, A., Crook, A. M., Levin, J. B., McCormack, S., & Kamali, A. (2017) · Reproductive Health · doi:10.1186/s12978-017-0296-3 · Cited by 3
“Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria.”
BackgroundInfluentialHidden heterogeneity: Uncovering patterns of adherence in microbicide trials for HIV prevention
Miller, L., Prieto‐Merino, D., Baisley, K. J., & Hayes, R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267011 · Cited by 8
In Vitro Virucidal Effect of Mouthrinse Containing C31G on Seasonal Influenza Viruses
Lee, D., Youn, H.-N., Park, J.-K., Kang, B.-H., Kang, J., Lee, J., Park, S., Choi, I., Lee, S., & Song, C. (2014) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1312.12055 · Cited by 3
Mpondo, B. C. T. (2016) · Journal of Sexually Transmitted Diseases · doi:10.1155/2016/7684768 · Cited by 4
“HIV [36, 37]; some were found to be potentially harmful [38].”
BackgroundGisselquist, D. (2011) · SSRN Electronic Journal · doi:10.2139/ssrn.1940999 · Cited by 4
“High risk[55-70] 14 12,131 NR 12,131 560 NR 560”
Recent Advances in Anogenital Antiretroviral Microbicides and Multimodal Delivery Systems
D’Cruz, O. J., & Uckun, F. M. (2012) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.1000144 · Cited by 2
“Early strategies to prevent the spread of sexual transmission of HIV-1 with first-generation vaginal antiviral agents led to the failure of 11 clinical trails with 6 microbicide candidates, nonoxynol-9, SAVVY®/C31G, cellulose sulfate, Carraguard®/PC-515, PRO 2000 and BufferGel® [15-19].”
BackgroundInfluentialSystematic review on effectiveness of prevention programs for sexually transmitted diseases (STD)
Ghazi, H. F., Taher, T. M. J., & Hassan, M. R. (2021) · Journal of Public Health · doi:10.1007/s10389-021-01499-w · Cited by 2
“Other studies also suggested ineffective use of microbicidal vaginal gel (Skoler-Karpoff et al. 2008; Feldblum et al. 2008; Microbicides Development Programme 2009] despite the advantage of using it under the women’s control irrespective of the men.”
BackgroundMolecular engineering of a banana lectin that inhibits HIV-1 replication
Swanson, M. D. (2010) · Deep Blue (University of Michigan) · Cited by 4
Enhancing Women’s Sexual Health: Prevention Measures in Diverse Populations of Women
Marrazzo, J. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4526-5_11 · Cited by 2
“5) [ 104 ] .”
Haire, B. G., & Jordens, C. F. C. (2013) · AJOB Primary Research · doi:10.1080/21507716.2013.782926 · Cited by 2
“…prevention have reduced HIV incidence in trial populations, regardless of whether the experimental intervention is effective, due to the increased emphasis on providing and promoting existing prevention methods such as condoms and STI treatment (e.g., Feldblum et al. 2008; Peterson et al. 2007).”
BackgroundParker, C., Corneli, A. L., Agot, K. E., Odhiambo, J. O., Asewe, J., Ahmed, K., Skhosana, J., Ratlhagana, M., Lanham, M., Wong, C., et al. (2014) · Open Access Journal of Clinical Trials · doi:10.2147/oajct.s68229 · Cited by 2
“We began planning for FEM-PrEP soon after the completion of the SAVVY trials in West Africa, also sponsored by FHI 360.(1,2) Investigators from these trials reported that they were unable to determine the effectiveness of the study product because of lower than expected HIV incidence within the study population.”
MethodBiocides in the health industry
Merlino, J., & Brown, M. H. (2010) · Microbiology Australia · doi:10.1071/ma10158 · Cited by 3
Transport phenomena and pharmacokinetics of anti-HIV microbicide drug delivery
Taşoğlu, S. (2011) · eScholarship (California Digital Library) · Cited by 2
Dual Protection Use to Prevent STIs and Unintended Pregnancy
Sales, J. M., Whiteman, M. K., Kottke, M., Madden, T. E., & DiClemente, R. J. (2012) · Infectious Diseases in Obstetrics and Gynecology · doi:10.1155/2012/972689 · Cited by 3
“[54] The Alan Guttmacher Institute, State Policies in Brief: Emergency Contraception, AGI, New York, NY, USA, 2011.”
BackgroundGood, better or best: A study of standards of prevention and care in HIV prevention trials
Haire, B. G. (2013) · The Sydney eScholarship Repository (The University of Sydney) · Cited by 2
Pro 2000: Next Steps for Microbicide Development
Karim, S. S. A., & Baxter, C. (2009) · Future Virology · doi:10.2217/fvl.09.22 · Cited by 2
Garratt, A., Muraleetharan, A., Fairhead, C., & Hill, A. M. (2025) · AIDS · doi:10.1097/qad.0000000000004232 · Cited by 3
Taylor, D. J., Lie, C.-C., Weaver, M. A., Tolley, E. E., Damme, L. V., Halpern, V., Feldblum, P. J., Ogunsola, F. T., Obunge, O., Ramjee, G., et al. (2010) · AIDS and Behavior · doi:10.1007/s10461-010-9822-9 · Cited by 1
“Recently investigated products have included diaphragms [ 1 ], anti-retroviral based prophylaxis [2], and topical microbicides [3‐5].”
BackgroundSelf-citationSexual Behavior Before and After Pregnancy Detection in Four Microbicide Trials
Rountree, W., Feldblum, P. J., Taylor, D. J., & Wevill, S. (2011) · AIDS and Behavior · doi:10.1007/s10461-011-0093-x · Cited by 1
“In SAVVY Nigeria, CS Nigeria, and CS South Africa, women reported a lower average proportion of sex acts not protected by condoms at the Subsequent Visit, whereas the proportion of unprotected sex acts increased slightly in CS Uganda and Benin and SAVVY Ghana (Table 2).”
MethodInfluentialSelf-citationFraietta, J. A., Mueller, Y. M., Lozenski, K. L., Ratner, D. M., Boesteanu, A. C., Hancock, A. S., Lackman-Smith, C., Zentner, I., CHAIKEN, I. M., Chung, S., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02991-14 · Cited by 1
“(carrageenan) (7, 19-21), have instructed the future development of microbicides in a number of 71 on F ebuary (1)1, 2021 by gest httpaac.”
BackgroundMicrobicides: Where are We Now and What Next?
McCormack, S. (2010) · HIV Therapy · doi:10.2217/hiv.10.50 · Cited by 1
Clinical Safety and Pharmacology Trial
Mauck, C. K., Thurman, A. R., & Schwartz, J. L. (2013) · Current topics in microbiology and immunology · doi:10.1007/82_2013_355 · Cited by 1
“Despite entering Phase III trials, none of these candidates were found to be effective (Van Damme et al. 2002; Peterson et al. 2007; Feldblum et al. 2008; Skoler-Karpoff et al. 2008; Van Damme et al. 2008; Halpern et al. 2008; Abdool Karim et al. 2011).”
BackgroundTopical Microbicide Acceptability
Morrow, K. M., Tolley, E. E., & Carballo‐Diéguez, A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-391059-2.00010-3 · Cited by 3
Kramzer, L. F. (2015) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Topical Microbicides for Human Immunodeficiency Virus and Sexually Transmitted Disease Prevention
Torjesen, K., Marrazzo, J. M., Hillier, S. L., & Cates, W. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-391059-2.00009-7 · Cited by 1
Uribe-Clavijo, M., Medina, L. F. O., Álvarez, Á. M., Cortés-Mancera, F., Cadavid-Jaramillo, Á. P., & Cardona-Maya, W. D. (2012) · Dialnet (Universidad de la Rioja) · Cited by 1
Comparison of HIV Risk Behaviors Between Clinical Trials and Observational Cohorts in Uganda
Abaasa, A. M., Nash, S., Mayanja, Y., Price, M. A., Fast, P., Kaleebu, P., & Todd, J. (2020) · AIDS and Behavior · doi:10.1007/s10461-020-02838-w · Cited by 2
HIV Epidemiology and Prevention
Ayesha, B. M., & Abdool, Q. (2011) · InTech eBooks · doi:10.5772/19532 · Cited by 1
Semen-mediated Enhancement of HIV Infection Markedly Impairs the Antiviral Efficacy of Microbicides
Zirafi, O., Kim, K.-A., Roan, N. R., Mayer, B., Kluge, S. F., Jiang, S., Greene, W. C., Kirchhoff, F., & Münch, J. (2014) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2014.5390.abstract · Cited by 1
Human immunodeficiency virus infection
Jamieson, D. J., King, C. C., & Kourtis, A. P. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139628938.026 · Cited by 2
Reduction of HIV-virion Transport for Prevention of HIV Transmission
Lai, B. E. (2010) · DukeSpace (Duke University) · Cited by 1
Microbicides: Molecular Strategies for Prevention of Sexually Transmitted Viral Disease
Fichorova, R. N. (2014) · ASM Press eBooks · doi:10.1128/9781555815493.ch15
The promise of vaginal microbicidesconfigurations of women's empowerment in a time of HIV
van der Zaag, A.-C. (2012) · Goldsmiths (University of London) · Cited by 1
Characterisation of llama antibody fragments able to act as HIV-1 entry inhibitors
Quigley, A. F. (2009) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 1
Pozzetto, B., Delézay, O., Hamzeh‐Cognasse, H., Lawrence, P., Lucht, F., & Bourlet, T. (2010) · Antibiotiques · doi:10.1016/j.antib.2010.01.005
Using DHS to Identify Sites for HIV Prevention Trials
Tolley, E. E., Weaver, M. A., & Albert, L. (2014) · African Population Studies · doi:10.11564/28-0-544
Walaza, S. (2011) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)
Tachedjian, G. (2010) · Microbiology Australia · doi:10.1071/ma10188
Preclinical safety assessment of Griffithsin-based vaginal microbicides.
Lasnik, A. B. (2013) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/795
“C31G / Savvy Non-specific inhibitor (detergent) Phase III study halted due to low HIV incidence in study population [5]”
BackgroundOlufunmilayo, A. R., Akobi, O. A., Omotayo, O. R., Anna, I. S., Oluwabunmi, A. I., Oladokun, O. S., Francis, A. A. S., Amos, I. E., Chimerenma, A. E., Abiobun, A. M., et al. (2015) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2015/15585
“[14] reported (1.”
Workowski, K., & Berman, S. M. (2010) · Cited by 1
Managing the HIV Epidemic in the Developing World – Progress and Challenges
van der Ryst, E., Palmer, M. J., & van Vuuren, C. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/9781849733496-00322
Targeted Combination HIV Prevention Packages to Halt the Global HIV
Daniels, B. B., & Gita Ramjee, H. (2012)
Graham, S. M. (2011) · TSpace (University of Toronto)
Microbicides for the Prevention of HIV
D’Cruz, O. J., & Uckun, F. M. (2014) · Pan Stanford eBooks · doi:10.1201/b17559-2
Antiretrovirals for HIV Prevention: The CAPRISA 004 Tenofovir Gel Trial
Baxter, C., Mansoor, L. E., Gengiah, T. N., Karim, S. S. A., & Karim, Q. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-47518-9_4
HIV Transmission Models: Lessons Learned for Microbicide Formulation Design
Mesquita, P. M. M., & Herold, B. C. (2014) · Pan Stanford eBooks · doi:10.1201/b17559-3
Raghvendra, G., & Vishwamohan, U. (2011)
Blanchard, K., Bostrom, A., Montgomery, E., van der Straten, A., Lince-Deroche, N., de Bruyn, G., Grossman, D., Gita Ramjee, H., & PADIAN, N. S. (2011)
Combating HIV/AIDS: biomedical approaches towards prevention
Mwangi, L. W., Lajoie, J., Oyugi, J. O., & Fowke, K. R. (2019) · African Journal of Biomedical Research
Gillies-Podgorecki, J., van Gaalen, S., Abdulwahid, T., Becker, M., Lê, M., Rabbani, R., Zarychanski, R., & Abou-Setta, A. M. (2021) · Research Square · doi:10.21203/rs.3.rs-137728/v1
Gynecological infectious disease
Bieber, E. J., Sanfilippo, J. S., Horowitz, I., & Shafi, M. I. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139628938.023
Asin, S., & Rollenhagen, C. (2013) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718056157.793481646
Abaasa, A. M., Mayanja, Y., Anywaine, Z., Kusemererwa, S., Ruzagira, E., & Kaleebu, P. (2022) · Research Square · doi:10.21203/rs.3.rs-1811079/v1
Abaasa, A. M., Mayanja, Y., Anywaine, Z., Kusemererwa, S., Ruzagira, E., & Kaleebu, P. (2022) · Research Square · doi:10.21203/rs.3.rs-1811079/v2
Reynolds, S. J., Quinn, T. C., & Sendagire, I. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-7959-7.00017-8
Hydrogels for vaginal drug delivery and other applications
das Neves, J., & Sarmento, B. F. C. C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22017-3.00011-1
Abaasa, A. M., Mayanja, Y., Anywaine, Z., Kusemererwa, S., Ruzagira, E., & Kaleebu, P. (2025) · Vaccines · doi:10.3390/vaccines13080844
“The literature indicates that the trial environment provides HIV risk reduction care beyond that in the observational studies [24,25].”
Bacterial and Viral Sexually Transmitted Infections
Hammo, A. H., Thamer, R. A., Alhafidh, N. M., Abdulrahman, T. S., & Saadi, A. M. (2025) · Pharaonic Journal of Science · doi:10.71428/pjs.2025.0211 · Cited by 1
Metadata
- Authors
- Feldblum, P. J., Adeiga, A., Bakare, R., Wevill, S., Lendvay, A., Obadaki, F., Olayemi, M. O., Wang, L., Nanda, K., & Rountree, W.
- Affiliations
- Family Health International 360 (US)
- Nigerian Institute of Medical Research (NG)
- University of Ibadan (NG)
- Corresponding author
- Feldblum, Paul J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-01-23
- Volume
- 3
- Issue
- 1
- Pages
- e1474
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2190795
- OpenAlex
- W2160780945
- Cited by
- 280
- References
- 28
- Citations by year
- 2025: 4 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 8 · 2020: 5 · 2019: 5 · 2018: 2 · 2017: 5 · 2016: 6 · 2015: 14 · 2014: 22 · 2013: 27 · 2012: 42
- FWCI
- 27.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- United States Agency for International Development (GPO-A-00-05-00022-00)
- U.S. Food and Drug Administration
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Keywords
- HIV prevention, vaginal microbicides, HIV seroconversion, HIV incidence, adverse events, chlamydia, vaginal infection
- MeSH terms
- Double-Blind Method, Female, Gels, Humans, Male, Nigeria, Patient Compliance, Placebos, Sexual Behavior, Vagina, HIV Infections, Anti-HIV Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
